Impact on Healthcare
Saving lives
in resistant times
Antimicrobial Resistance (AMR) is the silent pandemic that threatens our global healthcare systems and well-being in an unprecedented manner. At BioVersys, we fight AMR using innovation to save lives and improve patient outcomes. The Covid-19 global pandemic has highlighted the devastating impact of one infectious disease, let alone the potential simultaneous emergence of multiple pathogens that are already widespread in our communities.
Antimicrobial Resistance
on people is huge
Identifying unmet medical needs
Making people’s lives better
In March 1942, Anne Miller was near death. Infectious germs had made their way into her bloodstream. Doctors administered an experimental drug to her – Penicillin – and she recovered. She became the first person in the world to be saved by an antibiotic. Unfortunately, germs like the one that infected Anne Miller are becoming or have become resistant to antibiotics. Over the last few decades, we have seen limited to no progress in the introduction of new antibiotics. This is a ticking time bomb that threatens the world’s healthcare systems and endanger lives.
Rich and diverse pipelineImpactful solutions for AMR
Serious hospital infections -
A. baumannii
MDR-TB
(1) Community and hospital infections Staph. aureus
(2) Atopic dermatitis
ESKAPE pathogens
About us
Who we are
We are a passionate team, fighting against bacterial infections by focusing on research and development of small molecules that work by novel modes of action and against novel targets. BioVersys is an award winning privately-owned Swiss pharmaceutical company headquartered in Basel, Switzerland.
NewsroomLatest News
View all News